MME and Alzheimer disease: It was also notable that although these RAR-Ms were selected according to their potent genomic and non-genomic biological activities, there was significant variance in the genes they activated; for instance, DC525 reduced the levels of genes such as Mme, which is disadvantageous in the treatment of AD.